ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aprepitant

Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.

Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.

Drug pageAprepitant: every studyMany companies study it; this page follows only the 27 they lead. All 128 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 21, 200427 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck210 open or runningphase 4since Sep 21, 2004May 2, 2002none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since Jul 17, 2024Jul 17, 2024none ahead
Lahore Medical Research Center, LLPits history only10 open or runningphase 3since Feb 23, 2024Feb 23, 2024none ahead
LEO Pharmaits history only10 open or runningphase 2since Sep 18, 2013Sep 18, 2013none ahead
Nuformix Technologiesits history only10 open or runningphase 1since Mar 20, 2019Mar 20, 2019none ahead
Ono Pharmaceuticalits history only10 open or runningphase 2since Sep 13, 2005Sep 13, 2005none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 3since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 2, 2002First studies: 6 phase 3 studies in Depressive Disorder, MajorFirst studyNCT00035295, NCT00035282, NCT00035048 and 3 more
  2. Jul 22, 2002Phase 3 study in Depressive Disorder, MajorNCT00042029 · 324 enrolled
  3. Nov 4, 20022 phase 3 studies in Depressive Disorder, MajorNCT00048607, NCT00048594
  4. Mar 31, 2004Phase 3 study in VomitingNCT00080444 · 50 enrolled
  5. Sep 21, 2004Phase 3 study in NauseaNCT00092196 · 820 enrolled
  6. Sep 21, 2004Phase 4 study in NauseaNCT00092183 · 866 enrolled
  7. Jun 14, 2006Phase 3 study in VomitingNCT00337727 · 848 enrolled
  8. Jan 6, 20092 phase 1 studiesNCT00818259, NCT00819039
  9. Jul 23, 2009Phase 1 study in VomitingNCT00945321 · 42 enrolled
  10. Jul 31, 2009Phase 3 study in VomitingNCT00952341 · 421 enrolled
  11. Oct 6, 2009Phase 1 study in VomitingNCT00990821 · 188 enrolled
  12. May 26, 2011Phase 3 study in VomitingNCT01362530 · 307 enrolled
  13. Jul 5, 2012Phase 4 study in NauseaNCT01636947 · 494 enrolled
  14. Nov 19, 2012Phase 2 study in Post-operative NauseaNCT01732458 · 229 enrolled

TargetBeta

TACR1 →read by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
elinzanetantruleBayerphase 324
tradipitantruleVanda Pharmaceuticalsphase 319
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

All 21 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01732458Post-operative Nausea2CompletedSep 26, 2016229
NCT01636947Nausea4CompletedAug 4, 2014494
NCT01362530Vomiting3CompletedMar 14, 2013307
NCT00990821Vomiting1CompletedDec 2005188
NCT00952341Vomiting3CompletedApr 4, 2010421
NCT00945321Vomiting1CompletedMar 200942
NCT00819039Postoperative Nausea and Vomiting · United States, Brazil, Mexico and more1CompletedMar 12, 201398
NCT00818259Vomiting1TerminatedJan 20, 201492
NCT00337727Vomiting3CompletedOct 28, 2008848
NCT00092196Nausea3CompletedDec 1, 2004820
NCT00092183Nausea4CompletedDec 1, 2003866
NCT00080444Vomiting3CompletedSep 200650
NCT00048607Depressive Disorder, Major3CompletedDec 31, 2003600
NCT00048594Depressive Disorder, Major3CompletedDec 18, 2003800
NCT00042029Depressive Disorder, Major3CompletedOct 3, 2003324
NCT00035295Depressive Disorder, Major3CompletedDec 5, 2003584
NCT00035282Depressive Disorder, Major3CompletedDec 2003450
NCT00035048Depressive Disorder, Major3CompletedDec 29, 2003540
NCT00035009Depressive Disorder, Major3CompletedDec 22, 2003468
NCT00034983Depressive Disorder, Major3CompletedDec 29, 2003900
NCT00034944Depressive Disorder, Major3CompletedDec 17, 2003495

How it is read

Names in the registry

  • “aprepitant”, 8 entries
  • “Aprepitant”, 4 entries
  • “MK0869, aprepitant”, 4 entries
  • “Aprepitant Injection”, 2 entries
  • “Aprepitant 125 mg”, 2 entries

Codes read as this program: MK0869.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.